Role of opioid peptide Leu- Val-Val-hemorphin-6 in hepatocellular carcinoma

Mai Zhou,Ji-Run Peng,Zhao-Hui Zhong,Ying-Bin Chang,Gang-Jun Jiao,Xi-Sheng Leng,Xiang-Qun Tu
DOI: https://doi.org/10.11569/wcjd.v14.i31.3020
2006-01-01
World Chinese Journal of Digestology
Abstract:AIM: To assay the content differences of hemorphins between hepatocellular carcinoma (HCC) and normal liver tissues, and to explore the role of hemorphins in HCC.METHODS: The tissue samples were obtained from 12 patients with HCC, and peptides were isolated by mild acid elution from the surfaces of hepatocarcinoma and normal hepatic cells. The mixtures of peptides were analyzed by high performance liquid chromatography (HPLC) and mass spectrometer (MS). A differential comparison was made on the fractions of peptides between HCC and normal liver cells to screen some tumorspecific peptides. Finally, human hepatocarcinoma cell line HLE was treated with different concentrations of the obtained peptides(0, 10-7, 10-8, 10-9, 10-10, 10-11, 10-12 mol/L), and the growth and apoptosis of HLE cells were detected by MTT assay and ow cytometry (FCM), respectively.RESULTS: An opioid peptide Leu-Val-Val (LVV)-hemorphin-6 with Mr1160.76 was identified on the surfaces of HCC cells in 7 patients. LVV-hemorphin-6 inhibited the growth of HLE cells at different concentrations, especially at 10-7 and 10-8 mol/L (24 h: 10-7 vs 10-8: P = 0.044, 10-8 vs 10-9: P = 0.047; 48 h: 10-7 vs 10-8: P = 0.031, 10-8 vs 10-9: P = 0.040). Meanwhile, LVV-hemorphin-6 induced apoptosis of HLE cells and the apoptosis rates were 0.38% ± 0.09%, 20.23% ± 1.25%, 12.64% ± 2.15%, 1.65% ± 0.34%, when 0, 10-7, 10-8, 10-9 mol/L LVV-hemorphin-6 were used, respectively. However, naloxone could inhibit the above effect and the apoptosis rates were 0.41% ± 0.11%, 1.23% ± 0.45%, 0.98% ± 0.55%, 1.34% ± 0.43%, when the corresponding concentrations were used. The apoptosis rates were signifi-cantly different between the two groups (P < 0.05) as 10-7 and 10-8 mol/L LVV-hemorphin-6 were used.CONCLUSION: LVV-hemorphin-6 may be a product in the pathophysiological process of hepatocellular carcinoma, and it has suppressive effects on HCC cells by activating opiate receptors.
What problem does this paper attempt to address?